BTIG Maintains Buy on Climb Bio, Raises Price Target to $32
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.